Literature DB >> 6223421

The influence on pretransplant blood transfusions from random donors on immune parameters affecting cadaveric allograft survival.

R H Kerman, C T Van Buren, W Payne, S Flechner, G Agostino, S Conley, E Brewer, B D Kahan.   

Abstract

The number of pretransplant blood transfusions (BT) from random donors influences the recipient's immune response status and suppressor cell number and function, as well as allograft survival. The 54% one-year survival rate for 104 cadaveric renal allograft recipients treated with azathioprine and prednisone was divisible into two groups: 74.5% in 51 patients receiving greater than 5 BT and 34% for 53 patients with less than 5 BT (P less than 0.02). Transfusions enhanced the benefit of HLA A, B, and DR compatibility on graft survival: 33 recipients of well-matched grafts (less than 2 A, B, and 0-1 DR mismatches) had a one-year survival rate of 94% when pretreated with greater than 5 BT, compared with 38% when receiving less than 5 BT (P less than 0.05). The graft survival of 73% (36/49) displayed by patients determined preoperatively to be weak immune responders was significantly better than the 36% survival (20/55) demonstrated by strong immune responders (P less than 0.01). The transfusion history correlated with immune responder status: 76% (39/51) of patients receiving greater than 5 BT were weak immune responders, whereas 81% (43/53) of patients receiving less than 5 BT were strong immune responders (P less than 0.001). Ninety-two percent (12/13) of patients with greater than 5 BT, but only 58% (10/17) of patients with less than 5 BT, had a normal number of OKT8+ T suppressor cells. Only 1 X 10(5) mononuclear cells from patients with greater than 5 BT rather than 4 X 10(5) cells from patients with less than 5 BT caused 50% suppression of a third-party MLC. Thus, patients receiving greater than 5 BT are more likely to display weak immune responses, normal numbers of OKT8 cells, strong suppressor function in vitro, and prolonged allograft survival.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223421     DOI: 10.1097/00007890-198307000-00011

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  [Effect of the transfusion of blood and hemoderivatives on the prognosis of colorectal cancer].

Authors:  P Hermanek; I Guggenmoos-Holzmann; K T Schricker; T Resch; K Freudenberger; P Neidhardt; F P Gall
Journal:  Langenbecks Arch Chir       Date:  1989

2.  Evaluation of B-cell immunity in patients with pretransplant sensitization.

Authors:  D S Monos; M B Prystowsky; A I Levinson; C M Zmijewski
Journal:  J Clin Immunol       Date:  1988-05       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.